UKUK

Atlas Genetics raises £16.9m for market entry of Chlamydia-diagnostics

22.07.2011

Bristol – Atlas Genetics has raised £16.9m from a syndicate of new and existing investors led by Novartis Venture Funds, and Consort Medical plc. The series B round will be drawn down over three years to help to commercialize infectious disease tests, especially the global launch of the Velox diagnostic-kit for Chlamydia and gonorrhea. Commercial launch of the system is planned for 2012. The money will also be used for the development of other infectious disease tests and to expand the immunoassay capability of the Velox system.
Velox is a point of care-diagnostic system for a broad range of infectious diseases using either nucleic acid or immuno-assays. Atals’s CEO John Clarkson commented: “We are delighted to welcome the new investors at this time when the company’s first productn is being transferred to manufacture and the core capabilities of the sensor chemistry are being expanded.“
The new investors in this series B financing are Novartis Venture Funds, LSP (Life Sciences Partners), BB Biotech Ventures and Johnson & Johnson Development Corporation. The newly announced financing follows a £1.5 million round in February 2011 supported by Consort Medical plc and other investors. The Company has been funded previously, and continues to be supported, by YFM Equity Partners, Braveheart Investment Group, Wyvern Asset Management, the Crescent Seedcorn Fund and private investors.

UKUK

26.11.2010

Cambridge – Restoring absent p53 to lung tumour cells in mice can induce mregression in aggressive tumours, but does not have the same effect on early-stage tumours or less malignant cells residing in more advanced tumours. The...

UKUK

15.11.2010

Bristol – British biochemists have unravelled why metastatic prostate cancer cells do not stop migration on contact with non-cancer cells (Nature Cell Biol, DOI: 10.1038/ncb2122). Their findings may lay the foundations for...

UKUK

10.11.2010

Swansea – Probiotic bacteria can reduce the length of diarrhoea and significantly cut the risk of episodes lasting for more than four days. These are the findings of a new systematic review of data from 63 trials involving 8,014...

UKUK

04.11.2010

London – Broker and middle-market investment bank Piper Jaffray has announced it will stop selling securities for European issuers, which means biotech companies will have less access to full-service banks that offer a range of...

UKUK

03.11.2010

British drug delivery company Hospira (Leamington) has named Svend Andersen a Corporate VP and President for Europe, the Middle East and Africa. Under Andersen’s leadership, Hospira is aiming to increase its current market share...

UKUK

02.11.2010

London-based drug developer PepTcell Ltd. (London) has appointed Manfred Scheske as its CEO of Consumer Health. Scheske joins the firm from GlaxoSmithKline, where he worked for 25 years, most recently as President of Consumer...

UKUK

14.10.2010

London - The UK's Technology Strategy Board launched the Stratified Medicines Innovation Platform to provide over L50 million for personalized medicines research over the next five years. The platform will bring together...

UKUK

13.10.2010

Atlanta - The world's first clinical trial of a therapy derived from human embryonic stem cells has started, US-researchers announced on October 11th. A first patient with spinal cord injury was treated at Shepherd Center, a...

UKUK

17.09.2010

At the 10-year anniversary of the Human Genome Project, we stand poised to sequence entire cancer genomes from large numbers of clinical samples and gain an unprecedented insight into the genomic landscape of a wide range of...

Displaying results 71 to 80 out of 396

< Previous 71-80 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/7/article/atlas-genetics-raises-pound169m-for-market-entry-of-chlamydia-diagnostics.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.97 EUR11.43%
  • PROSENSA (NL)10.24 USD5.89%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK5.71%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)7.26 EUR-12.32%

TOP

  • WILEX (D)2.70 EUR229.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK52.6%
  • Allergy Therapeutics (UK)20.00 GBP34.4%

FLOP

  • HYBRIGENICS (F)1.68 EUR-29.7%
  • GW PHARMACEUTICALS (UK)418.50 GBP-20.1%
  • PHARMING (NL)0.44 EUR-20.0%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR284.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-70.3%

No liability assumed, Date: 31.07.2014


Current issue

All issues

Product of the week

Products